Genotech approved its 29th-term financial statements at the annual general meeting held on March 23, 2026. Based on the 2025 standalone disclosure, revenue was KRW 2,563 million, operating loss was KRW 870 million and net loss was KRW 1,146 million.
Revenue in 2024 was KRW 2,454 million with a net loss of KRW 760 million. In 2023, revenue was KRW 2,750 million and the net loss was KRW 263 million. In 2022, revenue was KRW 5,206 million with net income of KRW 1,755 million, and revenue has since fallen to roughly half that level.
At the end of 2025, total assets were KRW 10,504 million, total liabilities were KRW 955 million and total equity was KRW 9,549 million. Equity had fallen from KRW 11,455 million in 2023 and KRW 10,695 million in 2024.
Operating cash flow in 2024 was negative KRW 415 million, and investing cash flow was negative KRW 448 million. The same meeting approved an articles amendment adding medical device development, manufacturing and sales to the business purpose, which the company cited as the reason for the change. The share price stood at 1,199 won, within a 52-week range of 805 to 1,600 won.